By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Sagimet Biosciences Inc. (SGMT)

NASDAQ Currency in USD
$7.04
-$0.09
-1.26%
Last Update: 11 Sept 2025, 20:00
$218.25M
Market Cap
-3.85
P/E Ratio (TTM)
Forward Dividend Yield
$1.73 - $11.41
52 Week Range

SGMT Stock Price Chart

Explore Sagimet Biosciences Inc. interactive price chart. Choose custom timeframes to analyze SGMT price movements and trends.

SGMT Company Profile

Discover essential business fundamentals and corporate details for Sagimet Biosciences Inc. (SGMT) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

17 Jul 2023

Employees

14.00

CEO

David A. Happel

Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SGMT Financial Timeline

Browse a chronological timeline of Sagimet Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 Nov 2025

EPS estimate is -$0.41.

Earnings released on 13 Aug 2025

EPS came in at -$0.32 surpassing the estimated -$0.52 by +38.46%.

Earnings released on 8 May 2025

EPS came in at -$0.56 surpassing the estimated -$0.79 by +29.11%.

Earnings released on 12 Mar 2025

EPS came in at -$0.50 surpassing the estimated -$0.65 by +23.08%.

Earnings released on 14 Nov 2024

EPS came in at -$0.45 surpassing the estimated -$0.47 by +4.26%.

Earnings released on 14 Aug 2024

EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.

Earnings released on 15 May 2024

EPS came in at -$0.23 surpassing the estimated -$0.41 by +43.90%.

Earnings released on 25 Mar 2024

EPS came in at -$0.78 falling short of the estimated -$0.58 by -34.48%.

Earnings released on 13 Nov 2023

EPS came in at -$0.35 surpassing the estimated -$1.02 by +65.69%, while revenue for the quarter reached $2.00M .

Earnings released on 14 Jul 2023

EPS came in at -$35.80 falling short of the estimated -$0.50 by -7.06K%.

Earnings released on 31 Mar 2023

EPS came in at -$0.30 .

Earnings released on 31 Dec 2022

EPS came in at -$0.32 .

Earnings released on 30 Sept 2022

EPS came in at -$0.34 .

Earnings released on 30 Jun 2022

EPS came in at -$0.32 .

Earnings released on 31 Mar 2022

EPS came in at -$0.39 .

Earnings released on 31 Mar 2021

EPS came in at -$0.25 .

SGMT Stock Performance

Access detailed SGMT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run